BioSpace News Archive

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, and the U.S. Department of Defense (DOD) today announced Dynavax has executed an agreement for approximately $22 million over two and a half years to develop a recombinant plague vaccine adjuvanted with CpG 1018®.

Mirion Technologies, Inc. (“Mirion”), a global provider of detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced the acquisition of the Dosimetry Badge brand—a small, US-based distributor of personal dosimeter badges.

IVERIC bio, Inc. reported that on October 1, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to eight newly-hired, non-executive employees.

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest product, Aura GT.

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced the successful completion of a Phase 1 clinical trial investigating its optimized Peptelligence oral tablet formulation of leuprolide.

Harold S. Bernstein, M.D., Ph.D. Named Senior Vice President, Chief Medical Officer and Head of Clinical Development Ganesh Vedantham, Ph.D. Named Senior Vice President, Technical Development

ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management Systems (VLMS), today announced the appointment of Mike Hicks as Chief Technology Officer.

Assertio Holdings, Inc. announced that the Company’s Chief Executive Officer, Dan Peisert, and Chief Financial Officer, Paul Schwichtenberg, will present and host individual meetings with investors at the following events:.

BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, announced today that it signed a formal, worldwide partnership agreement with global contract research organization Clinical Trial and Consulting Services (CTI).

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced it has signed an agreement with pharmacy benefit manager MC-Rx, which places Theranica’s flagship Nerivio® device for acute treatment of migraine under MC-Rx’s Pharmacy Benefit formulary.